Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Small Cell Carcinoma HELP
Based on 56,289 articles published since 2009
|||| 67 

These are the 56289 published articles about Carcinoma, Small Cell that originated from Worldwide during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases. 2019

Ponce, Santiago / Bruna, Jordi / Juan, Oscar / López, Rafael / Navarro, Alejandro / Ortega, Ana Laura / Puente, Javier / Verger, Eugènia / Bartolomé, Adela / Nadal, Ernest. ·Lung Cancer Clinical Research Unit, Hospital Universitario 12 de Octubre, Av. Cordoba, s/n, 28041 Madrid, Spain. Electronic address: sponceaix@gmail.com. · Neuro-Oncology Unit, Bellvitge University Hospital-ICO, Carrer de la Feixa Llarga, s/n, 08907, L'Hospitalet de Llobregat, Barcelona, Spain; Clinical Research in Solid Tumors (CReST) and Neuro-Oncology Group. Oncobell, IDIBELL, Avda Gran Via 199-203, 08907, L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: jbruna@bellvitgehospital.cat. · Medical Oncology Service, Hospital Universitario y Politécnico La Fe, Valencia, Avda. de Fernando Abril Martorell, nº 106, 46026, Valencia, Spain. Electronic address: juan_osc@gva.es. · Medical Oncology Unit. Hospital Clínico Universitario de Valladolid, Av. Ramón y Cajal, 3, 47003, Valladolid, Spain. Electronic address: rafalopezcastro@yahoo.es. · Medical Oncology. Hospital Vall d'Hebron, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain. Electronic address: alexnavarro84@gmail.com. · Oncology Research Unit, Complejo Hospitalario de Jaén, Av. del Ejército Español, 10, 23007, Jaén, Spain. Electronic address: analauraortega@gmail.com. · GU, Thoracic and Melanoma Cancer Unit, Medical Oncology Department, Assistant Professor of Medicine, Complutense University. Hospital Clinico Universitario San Carlos, Calle del Prof Martín Lagos, s/n, 28040, Madrid, Spain. Electronic address: javierpuente.hcsc@gmail.com. · Radiation Oncology Department, Hospital Clínic de Barcelona, Carrer de Villarroel, 170, 08036, Barcelona, Spain. Electronic address: everger@clinic.cat. · Radiotherapy Oncology Department. Hospital Universitario 12 de Octubre, Av. Cordoba, s/n, 28041, Madrid, Spain. Electronic address: adelabartolome@gmail.com. · Clinical Research in Solid Tumors (CReST) and Neuro-Oncology Group. Oncobell, IDIBELL, Avda Gran Via 199-203, 08907, L'Hospitalet de Llobregat, Barcelona, Spain; Thoracic Oncology Unit, Department of Medical Oncology, Catalan Institute of Oncology. Avda Gran Via 199-203, 08907, L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: esnadal@iconcologia.net. ·Crit Rev Oncol Hematol · Pubmed #31092376.

ABSTRACT: The presence of an epidermal growth factor receptor (EGFR) mutation is associated with higher incidence of brain metastases in patients with non-small cell lung cancer (NSCLC); however, patients with synchronous brain metastases at diagnosis have generally been excluded from clinical trials. As there is limited clinical evidence for managing this patient population, a multidisciplinary group of Spanish medical and radiation oncologists, and neuro-oncologist with expertise treating brain metastases in lung cancer patients met with the aim of reaching and developing an expert opinion consensus on the management of patients with EGFR mutated NSCLC with brain metastases. This consensus contains 26 recommendations and 20 conclusion statements across 21 questions in 7 areas, as well as a first-line treatment algorithm.

2 Guideline The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. 2019

Akamatsu, Hiroaki / Ninomiya, Kiichiro / Kenmotsu, Hirotsugu / Morise, Masahiro / Daga, Haruko / Goto, Yasushi / Kozuki, Toshiyuki / Miura, Satoru / Sasaki, Takaaki / Tamiya, Akihiro / Teraoka, Shunsuke / Tsubata, Yukari / Yoshioka, Hiroshige / Hattori, Yoshihiro / Imamura, Chiyo K / Katsuya, Yuki / Matsui, Reiko / Minegishi, Yuji / Mizugaki, Hidenori / Nosaki, Kaname / Okuma, Yusuke / Sakamoto, Setsuko / Sone, Takashi / Tanaka, Kentaro / Umemura, Shigeki / Yamanaka, Takeharu / Amano, Shinsuke / Hasegawa, Kazuo / Morita, Satoshi / Nakajima, Kazuko / Maemondo, Makoto / Seto, Takashi / Yamamoto, Nobuyuki. ·Internal Medicine III, Wakayama Medical University, Wakayama, Japan. · Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. · Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. · Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Aichi, Japan. · Osaka City General Hospital, Osaka, Japan. · Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. · Clinical Research Center, Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Ehime, Japan. · Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan. · Respiratory Center, Asahikawa Medical University Hospital, Hokkaido, Japan. · National Hospital Organization Kinki-chuo Chest Medical Center, Osaka, Japan. · Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, Shimane, Japan. · Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan. · Department of Thoracic Oncology, Hyogo Cancer Center, Hyogo, Japan. · Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan. · Department of Surgery, University of California San Diego, California, USA. · National Cancer Center Hospital East, Chiba, Japan. · Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. · First Department of Medicine, Hokkaido University Hospital, Hokkaido, Japan. · Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. · Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan. · Kyushu University Hospital, Fukuoka, Japan. · Regional Respiratory Symptomatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. · Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. · Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan. · Department of Biostatistics, Yokohama City University School of Medicine, Kanagawa, Japan. · Japan Federation of Cancer Patient Groups, Tokyo, Japan. · Japan Lung Cancer Alliance, Tokyo, Japan. · Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan. · Shizuoka Cancer Center, Shizuoka, Japan. · Division of Pulmonary Medicine, Allergry and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan. · Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. setocruise@gmail.com. ·Int J Clin Oncol · Pubmed #31049758.

ABSTRACT: According to rapid development of chemotherapy in advanced non-small cell lung cancer (NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually since 2010. In this latest version, all of the procedure was carried out in accordance with grading of recommendations assessment, development and evaluation (GRADE) system. It includes comprehensive literature search, systematic review, and determination of the recommendation by multidisciplinary expert panel which consisted of medical doctors, pharmacists, nurses, statisticians, and patients from patient advocacy group. Recently, we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors. Thus, the guideline proposes to categorize patients into three entities: (1) driver oncogene-positive, (2) PD-L1 ≥ 50%, and (3) others. Based on this subgroup, 31 clinical questions were described. We believe that this attempt enables clinicians to choose appropriate treatment easier. Here, we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC, stages IV.

3 Guideline The American Society of Clinical Oncology-endorsed American Society for Radiation Oncology Evidence-Based Guideline of stereotactic body radiotherapy for early-stage non-small cell lung cancer: An expert opinion. 2019

Guckenberger, Matthias / Aerts, Joachim G / Van Schil, Paul / Weder, Walter. ·Department for Radiation Oncology, University Hospital Zurich, University Zurich, Zurich, Switzerland. · Department of Pulmonary Diseases, Erasmus MC, Rotterdam, The Netherlands. · Department of Thoracic and Vascular Surgery, Antwerp University Hospital and Antwerp University, Antwerp, Belgium. · Department of Thoracic Surgery, University Hospital Zurich, University Zurich, Zurich, Switzerland. Electronic address: walter.weder@usz.ch. ·J Thorac Cardiovasc Surg · Pubmed #30557952.

ABSTRACT: -- No abstract --

4 Guideline NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. 2018

Kalemkerian, Gregory P / Loo, Billy W / Akerley, Wallace / Attia, Albert / Bassetti, Michael / Boumber, Yanis / Decker, Roy / Dobelbower, M Chris / Dowlati, Afshin / Downey, Robert J / Florsheim, Charles / Ganti, Apar Kishor P / Grecula, John C / Gubens, Matthew A / Hann, Christine L / Hayman, James A / Heist, Rebecca Suk / Koczywas, Marianna / Merritt, Robert E / Mohindra, Nisha / Molina, Julian / Moran, Cesar A / Morgensztern, Daniel / Pokharel, Saraswati / Portnoy, David C / Rhodes, Deborah / Rusthoven, Chad / Sands, Jacob / Santana-Davila, Rafael / Williams, Charles C / Hoffmann, Karin G / Hughes, Miranda. · ·J Natl Compr Canc Netw · Pubmed #30323087.

ABSTRACT: The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease management. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for SCLC regarding immunotherapy, systemic therapy, and radiation therapy. For the 2018 update, new sections were added on "Signs and Symptoms of SCLC" and "Principles of Pathologic Review."

5 Guideline Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2018

Planchard, D / Popat, S / Kerr, K / Novello, S / Smit, E F / Faivre-Finn, C / Mok, T S / Reck, M / Van Schil, P E / Hellmann, M D / Peters, S / Anonymous1441552. ·Department of Medical Oncology, Thoracic Group, Gustave-Roussy Villejuif, France. · Royal Marsden Hospital, London. · Aberdeen Royal Infirmary, Aberdeen University Medical School, Aberdeen, UK. · Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy. · Thoracic Oncology Service, Netherlands Cancer Institute, Amsterdam, The Netherlands. · Division of Cancer Sciences, University of Manchester, Manchester, UK. · Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China. · LungenClinic Airway Research Center North (ARCN), German Center for Lung Research, Grosshansdorf, Germany. · Department of Thoracic and Vascular Surgery, Antwerp University Hospital and Antwerp University, Antwerp, Belgium. · Weill Cornell Medical College, New York, USA. · Medical Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. ·Ann Oncol · Pubmed #30285222.

ABSTRACT: -- No abstract --

6 Guideline Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy. 2018

Sun, A / Durocher-Allen, L D / Ellis, P M / Ung, Y C / Goffin, J R / Ramchandar, K / Darling, G. ·Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address: ccopgi@mcmaster.ca. · Program in Evidence-Based Care, McMaster University, Hamilton, Ontario, Canada. · Medical Oncology, Juravinski Cancer Centre, Hamilton, Ontario, Canada; Department of Oncology, McMaster University, Hamilton, Ontario, Canada. · Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada. · Medical Oncology, Juravinski Cancer Centre, Hamilton, Ontario, Canada. · Radiation Oncology, Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada. · Thoracic Surgery, Toronto General Hospital, Toronto, Ontario, Canada. ·Clin Oncol (R Coll Radiol) · Pubmed #30007803.

ABSTRACT: AIMS: We investigated the efficacy of adding radiotherapy to chemotherapy in patients with extensive stage small cell lung cancer (ES-SCLC) and the appropriate timing, dose and schedule of treatment for patients with ES-SCLC or limited stage SCLC (LS-SCLC). MATERIALS AND METHODS: The guideline was developed by Cancer Care Ontario's Program in Evidence-Based Care and by the Lung Cancer Disease Site Group through a systematic review of randomised controlled trials. KEY RECOMMENDATIONS: In patients with LS-SCLC (stage I, II and III), the addition of thoracic radiotherapy to standard chemotherapy is recommended. However, there is no clear evidence to inform definitive recommendations for optimal timing, sequential versus concurrent therapies and optimal dose or regimen. In patients with LS-SCLC, etoposide-cisplatin is the preferred regimen for adults who are being treated with combined modality therapy with curative intent. In patients with ES-SCLC (stage IV), there is insufficient evidence to recommend the addition of thoracic radiotherapy to standard chemotherapy as a standard practice for survival benefit; however, it could be considered on a case-by-case basis to reduce local recurrence. In patients with ES-SCLC, a platinum agent plus etoposide is the preferred regimen for adult patients who are being treated with combined modality therapy. Cisplatin and irinotecan represents an alternative treatment option to this, but is associated with increased rates of adverse events such as diarrhoea.

7 Guideline NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. 2018

Ettinger, David S / Aisner, Dara L / Wood, Douglas E / Akerley, Wallace / Bauman, Jessica / Chang, Joe Y / Chirieac, Lucian R / D'Amico, Thomas A / Dilling, Thomas J / Dobelbower, Michael / Govindan, Ramaswamy / Gubens, Matthew A / Hennon, Mark / Horn, Leora / Lackner, Rudy P / Lanuti, Michael / Leal, Ticiana A / Lilenbaum, Rogerio / Lin, Jules / Loo, Billy W / Martins, Renato / Otterson, Gregory A / Patel, Sandip P / Reckamp, Karen / Riely, Gregory J / Schild, Steven E / Shapiro, Theresa A / Stevenson, James / Swanson, Scott J / Tauer, Kurt / Yang, Stephen C / Gregory, Kristina / Hughes, Miranda. · ·J Natl Compr Canc Netw · Pubmed #30006423.

ABSTRACT: The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the targeted therapy and immunotherapy sections in the NCCN Guidelines. For the 2018 update, a new section on biomarkers was added.

8 Guideline SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer. 2018

Fernández Pérez, G / Sánchez Escribano, R / García Vicente, A M / Luna Alcalá, A / Ceballos Viro, J / Delgado Bolton, R C / Vilanova Busquets, J C / Sánchez Rovira, P / Fierro Alanis, M P / García Figueiras, R / Alés Martínez, J E. ·Departamento de Radiología, Hospital Universitario Río Hortega, Valladolid, España. · Departamento de Oncología Médica, Hospital Universitario de Burgos, Burgos, España. · Departamento de Medicina Nuclear, Hospital General Universitario, Ciudad Real, España. · Clínica Las Nieves, Health Time, Jaén, España; Department of Radiology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio, Estados Unidos. Electronic address: aluna70@htime.org. · Unidad de Oncología Médica, Hospital Nuestra Señora de Sonsoles, Complejo Asistencial de Ávila, Ávila, España. · Departamento de Diagnóstico por Imagen (Radiología) y Medicina Nuclear, Hospital de San Pedro y (CIBIR), Universidad de La Rioja, Logroño, España. · Servicio de Radiología, Institut Català de la Salut (IDI), Girona, Clínica Girona, Girona, España. · Departamento de Oncología Médica, Hospital Universitario de Jaén, Jaén, España. · Departamento de Medicina Nuclear, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, España. · Departamento de Radiología, Complexo Hospitalario Santiago de Compostela, Santiago de Compostela, España. ·Radiologia · Pubmed #29807678.

ABSTRACT: Imaging in oncology is an essential tool for patient management but its potential is being profoundly underutilized. Each of the techniques used in the diagnostic process also conveys functional information that can be relevant in treatment decision making. New imaging algorithms and techniques enhance our knowledge about the phenotype of the tumor and its potential response to different therapies. Functional imaging can be defined as the one that provides information beyond the purely morphological data, and include all the techniques that make it possible to measure specific physiological functions of the tumor, whereas molecular imaging would include techniques that allow us to measure metabolic changes. Functional and molecular techniques included in this document are based on multi-detector computed tomography (CT), 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET), magnetic resonance imaging (MRI), and hybrid equipments, integrating PET with CT (PET/CT) or MRI (PET-MRI). Lung cancer is one of the most frequent and deadly tumors although survival is increasing thanks to advances in diagnostic methods and new treatments. This increased survival poises challenges in terms of proper follow-up and definitions of response and progression, as exemplified by immune therapy-related pseudoprogression. In this consensus document, the use of functional and molecular imaging techniques will be addressed to exploit their current potential and explore future applications in the diagnosis, evaluation of response and detection of recurrence of advanced NSCLC.

9 Guideline ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. 2018

Nestle, Ursula / De Ruysscher, Dirk / Ricardi, Umberto / Geets, Xavier / Belderbos, Jose / Pöttgen, Christoph / Dziadiuszko, Rafal / Peeters, Stephanie / Lievens, Yolande / Hurkmans, Coen / Slotman, Ben / Ramella, Sara / Faivre-Finn, Corinne / McDonald, Fiona / Manapov, Farkhad / Putora, Paul Martin / LePéchoux, Cécile / Van Houtte, Paul. ·Department of Radiation Oncology, Kliniken Maria Hilf, Moenchengladbach, Germany; Department of Radiation Oncology, University Hospital Freiburg, Germany. Electronic address: ursula.nestle@mariahilf.de. · Maastricht University Medical Center, Department of Radiation Oncology (Maastro clinic), GROW School for Oncology and Developmental Biology, The Netherlands; KU Leuven, Radiation Oncology, Belgium. · Department of Oncology, University of Turin, Italy. · Department of Radiation Oncology, Cliniques universitaires Saint-Luc, MIRO - IREC Lab, UCL, Belgium. · Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. · Department of Radiation Oncology, West German Tumor Centre, University of Duisburg-Essen Medical School, Germany. · Department of Oncology and Radiotherapy, Medical University of Gdańsk, Poland. · Maastricht University Medical Center, Department of Radiation Oncology (Maastro clinic), GROW School for Oncology and Developmental Biology, The Netherlands. · Department of Radiation Oncology, Ghent University Hospital, Belgium. · Catharina Hospital, Department of Radiation Oncology, Eindhoven, The Netherlands. · Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands. · Department of Radiation Oncology, Campus Bio-Medico University, Rome, Italy. · University of Manchester & The Christie NHS Foundation Trust, Manchester, UK. · Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK. · Department of Radiation Oncology, University Hospital, LMU Munich, Germany. · Department of Radiation Oncology, Kantonsspital St. Gallen, Switzerland; Medical Faculty, University of Bern, Switzerland. · Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France. · Department Radiation Oncology, Institut Bordet, Université Libre Bruxelles, Belgium. ·Radiother Oncol · Pubmed #29605476.

ABSTRACT: Radiotherapy (RT) plays a major role in the curative treatment of locally advanced non-small cell lung cancer (NSCLC). Therefore, the ACROP committee was asked by the ESTRO to provide recommendations on target volume delineation for standard clinical scenarios in definitive (chemo)radiotherapy (RT) and adjuvant RT for locally advanced NSCLC. The guidelines given here are a result of the evaluation of a structured questionnaire followed by a consensus discussion, voting and writing procedure within the committee. Hence, we provide advice for methods and time-points of diagnostics and imaging before the start of treatment planning and for the mandatory and optional imaging to be used for planning itself. Concerning target volumes, recommendations are given for GTV delineation of primary tumour and lymph nodes followed by issues related to the delineation of CTVs for definitive and adjuvant radiotherapy. In the context of PTV delineation, recommendations about the management of geometric uncertainties and target motion are given. We further provide our opinions on normal tissue delineation and organisational and responsibility questions in the process of target volume delineation. This guideline intends to contribute to the standardisation and optimisation of the process of RT treatment planning for clinical practice and prospective studies.

10 Guideline [PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists]. 2018

Lantuejoul, Sylvie / Adam, Julien / Girard, Nicolas / Duruisseaux, Mickael / Mansuet-Lupo, Audrey / Cazes, Aurélie / Rouquette, Isabelle / Gibault, Laure / Garcia, Stéphane / Antoine, Martine / Vignaud, Jean Michael / Galateau-Sallé, Françoise / Sagan, Christine / Badoual, Cécile / Penault-Llorca, Frédérique / Damotte, Diane / Anonymous5301006. ·Département de biopathologie et département de recherche translationnelle et d'innovations, centre Léon-Bérard UNICANCER, 28, rue Laennec, 69008 Lyon, France; Inserm U1209/CNRS 5309, Grenoble-Alpes université, Institute for Advanced Biosciences, 38700 La Tronche, France. Electronic address: sylvie.lantuejoul@lyon.unicancer.fr. · Département de biologie et pathologie médicales, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif, France; Inserm U981, Gustave-Roussy, 94805 Villejuif, France. · Institut du thorax Curie-Montsouris, institut Curie, 75005 Paris, France; Université Claude-Bernard Lyon 1, université de Lyon, 69622 Villeurbanne, France. · Inserm 1052, CNRS 5286, centre de recherche en cancérologie de Lyon, institut de cancérologie des Hospices Civiles de Lyon (IC-HCL), service de pneumologie, hôpital Louis-Pradel, 69008 Lyon, France. · Département de pathologie, hôpital Cochin, université Paris Descartes, Assistance publique-hôpitaux de Paris, 74014 Paris, France. · Inserm UMR1152, département de pathologie, hôpital Bichat, université Paris Diderot, 75018 Paris, France. · Département de pathologie, IUCT Oncopôle, CHU de Toulouse, 31059 Toulouse, France. · Département de pathologie, hôpital européen Georges-Pompidou, Assistance publique-hôpitaux de Paris, 75015 Paris, France; Inserm UMR-S970, Paris centre de recherche cardiovasculaire, Georges-Pompidou European Hospital, 75015 Paris, France. · Département de Pathologie, hôpital Nord, Assistance publique-hôpitaux de Marseille, Aix-Marseille Université, CRCM, 13015 Marseille, France. · Service d'anatomie pathologique, hôpital Tenon AP-HP, 75020 Paris, France; UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France. · Département de pathologie, CHRU de Nancy, 54035 Nancy, France; Inserm 1256, université de Lorraine, 54505 Vandœuvre-lès-Nancy, France. · Centre National Référent MESOPATH, Base Clinicobiologique nationale MESOBANK, Registre multicentrique MESONAT centre Leon-Bérard, département de biopathologie, 69008 Lyon, France. · Inserm U1087, institut du Thorax, service d'anatomie et cytologique pathologiques, hôpital Hotel-Dieu, CHU de Nantes, 44093 Nantes, France. · UMR Inserm 1240 IMoST, Centre Jean-Perrin, département de pathologie, université Clermont-Auvergne, 63011 Clermont-Ferrand, France. ·Ann Pathol · Pubmed #29571563.

ABSTRACT: Lung cancer is the leading cause of cancer death in France with low response rates to conventional chemotherapy. Nevertheless, new therapies have emerged recently, among which PD1 immune checkpoint inhibitors (ICI), such as nivolumab (OPDIVO

11 Guideline Behavioral Counseling to Prevent Skin Cancer: US Preventive Services Task Force Recommendation Statement. 2018

Anonymous3771582 / Grossman, David C / Curry, Susan J / Owens, Douglas K / Barry, Michael J / Caughey, Aaron B / Davidson, Karina W / Doubeni, Chyke A / Epling, John W / Kemper, Alex R / Krist, Alex H / Kubik, Martha / Landefeld, Seth / Mangione, Carol M / Silverstein, Michael / Simon, Melissa A / Tseng, Chien-Wen. ·Kaiser Permanente Washington Health Research Institute, Seattle. · University of Iowa, Iowa City. · Veterans Affairs Palo Alto Health Care System, Palo Alto, California. · Stanford University, Stanford, California. · Harvard Medical School, Boston, Massachusetts. · Oregon Health & Science University, Portland. · Columbia University, New York, New York. · University of Pennsylvania, Philadelphia. · Virginia Tech Carilion School of Medicine, Roanoke. · Nationwide Children's Hospital, Columbus, Ohio. · Fairfax Family Practice Residency, Fairfax, Virginia. · Virginia Commonwealth University, Richmond. · Temple University, Philadelphia, Pennsylvania. · University of Alabama at Birmingham. · University of California, Los Angeles. · Boston University, Boston, Massachusetts. · Northwestern University, Evanston, Illinois. · University of Hawaii, Honolulu. · Pacific Health Research and Education Institute, Honolulu, Hawaii. ·JAMA · Pubmed #29558558.

ABSTRACT: Importance: Skin cancer is the most common type of cancer in the United States. Although invasive melanoma accounts for only 2% of all skin cancer cases, it is responsible for 80% of skin cancer deaths. Basal and squamous cell carcinoma, the 2 predominant types of nonmelanoma skin cancer, represent the vast majority of skin cancer cases. Objective: To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on behavioral counseling for the primary prevention of skin cancer and the 2009 recommendation on screening for skin cancer with skin self-examination. Evidence Review: The USPSTF reviewed the evidence on whether counseling patients about sun protection reduces intermediate outcomes (eg, sunburn or precursor skin lesions) or skin cancer; the link between counseling and behavior change, the link between behavior change and skin cancer incidence, and the harms of counseling or changes in sun protection behavior; and the link between counseling patients to perform skin self-examination and skin cancer outcomes, as well as the harms of skin self-examination. Findings: The USPSTF determined that behavioral counseling interventions are of moderate benefit in increasing sun protection behaviors in children, adolescents, and young adults with fair skin types. The USPSTF found adequate evidence that behavioral counseling interventions result in a small increase in sun protection behaviors in adults older than 24 years with fair skin types. The USPSTF found inadequate evidence on the benefits and harms of counseling adults about skin self-examination to prevent skin cancer. Conclusions and Recommendation: The USPSTF recommends counseling young adults, adolescents, children, and parents of young children about minimizing exposure to UV radiation for persons aged 6 months to 24 years with fair skin types to reduce their risk of skin cancer. (B recommendation) The USPSTF recommends that clinicians selectively offer counseling to adults older than 24 years with fair skin types about minimizing their exposure to UV radiation to reduce risk of skin cancer. Existing evidence indicates that the net benefit of counseling all adults older than 24 years is small. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the presence of risk factors for skin cancer. (C recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of counseling adults about skin self-examination to prevent skin cancer. (I statement).

12 Guideline Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline Summary. 2018

Schneider, Bryan J / Daly, Megan E / Kennedy, Erin B / Stiles, Brendon M. ·University of Michigan, Ann Arbor, MI; University of California, Davis, CA; American Society of Clinical Oncology, Alexandria, VA; and Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY. ·J Oncol Pract · Pubmed #29257717.

ABSTRACT: -- No abstract --

13 Guideline Appendix 8: Metastatic non-small-cell lung cancer (2): eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours). 2017

Anonymous5000918. · ·Ann Oncol · Pubmed #28881929.

ABSTRACT: -- No abstract --

14 Guideline Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours). 2017

Anonymous4990918. · ·Ann Oncol · Pubmed #28881928.

ABSTRACT: -- No abstract --

15 Guideline Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2017

Postmus, P E / Kerr, K M / Oudkerk, M / Senan, S / Waller, D A / Vansteenkiste, J / Escriu, C / Peters, S / Anonymous4880918. ·The Clatterbridge Cancer Centre and Liverpool Heart and Chest Hospital, Liverpool. · University of Aberdeen, Aberdeen, UK. · Center for Medical Imaging, University of Groningen, Groningen. · Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands. · Department of Thoracic Surgery, University Hospitals of Leicester NHS Trust, Leicester, UK. · University Hospitals KU Leuven, Leuven, Belgium. · Oncology Department, Service d'Oncologie Médicale, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. ·Ann Oncol · Pubmed #28881918.

ABSTRACT: -- No abstract --

16 Guideline ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. 2017

Guckenberger, Matthias / Andratschke, Nicolaus / Dieckmann, Karin / Hoogeman, Mischa S / Hoyer, Morten / Hurkmans, Coen / Tanadini-Lang, Stephanie / Lartigau, Eric / Méndez Romero, Alejandra / Senan, Suresh / Verellen, Dirk. ·Department of Radiation Oncology, University Hospital Zürich, Switzerland. Electronic address: matthias.guckenberger@usz.ch. · Department of Radiation Oncology, University Hospital Zürich, Switzerland. · Department of Radiation Oncology, Medical University of Vienna, Austria. · Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. · Department of Radiation Oncology, Aarhus University Hospital, Denmark. · Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands. · Department of Radiation Oncology, Centre Oscar Lambret, Lille, France. · Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands. · Department of Radiation Oncology, UZ Brussel (VUB), Belgium. ·Radiother Oncol · Pubmed #28687397.

ABSTRACT: BACKGROUND: Stereotactic body radiotherapy (SBRT) has become the standard of care for medically inoperable patients with peripherally located, early stage non-small cell lung cancer (NSCLC), and for those refusing surgical resection. Despite the availability of national and international guidelines, there exists substantial variability in many aspects of SBRT practice. METHODS: The ESTRO ACROP guideline is based on a questionnaire covering all aspects of SBRT implementation and practice (n=114 items). The questionnaire was answered by the 11 faculty members of the ESTRO course "Clinical practice and implementation of image-guided SBRT" and their 8 institutions. RESULTS: Agreement by >50% of the institutions was achieved in 72% of all items. Only 8/57 technologies and techniques were identified as mandatory for SBRT while 32/57 were considered as optional. In contrast, quality-assurance related elements were considered as mandatory in 12/24 items. A consensus of risk-adapted SBRT fractionation was achieved with 3×15Gy for peripherally located lesions and 4×12Gy (PTV D95-D99; D CONCLUSIONS: This ACROP guideline achieved detailed recommendations in all aspects of SBRT implementation and practice, which will contribute to further standardization of SBRT for peripherally located early stage NSCLC.

17 Guideline Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). 2017

Moureau-Zabotto, Laurence / Vendrely, Veronique / Abramowitz, Laurent / Borg, Christophe / Francois, Eric / Goere, Diane / Huguet, Florence / Peiffert, Didier / Siproudhis, Laurent / Ducreux, Michel / Bouché, Olivier. ·Paoli Calmettes Institute, Marseille, France. Electronic address: moureaul@ipc.unicancer.fr. · CHU Saint Andre, Bordeaux, France. · CHU Bichat, Paris, France. · CHU Jean-Minjoz, Besançon, France. · Centre Antoine Lacassagne, Nice, France. · Gustave Roussy, Villejuif, France. · CHU Tenon, Paris, France. · Cancerology Institute of Lorraine (Centre Alexis Vautrin), Vandœuvre-lès-Nancy, France. · CHU de Rennes, Rennes, France. · CHU de Reims, Reims Cedex, France. ·Dig Liver Dis · Pubmed #28610905.

ABSTRACT: INTRODUCTION: This document is a summary of the French Intergroup guidelines regarding the management of anal carcinomas, published in November 2016. METHODS: It is a collaborative work produced under the auspices of the majority of the French medical societies involved in the management of anal cancer. It is based on the previous guidelines published in 2010. Recommendations are graded in three categories, according to the amount of evidence found in the literature. RESULTS: Non-metastatic anal carcinomas can be divided into two risk groups, according to magnetic resonance imaging (MRI) or endorectal-ultrasonograpy. Localized small cancers (T1N0) are mainly treated by exclusive radiation therapy in the case of cancers of the anal canal, or by surgery in the case of cancers of the anal margin. The recommended treatment of locally advanced tumours (T2-T4, N0-N2) is definitive concomitant radio-chemotherapy. Salvage surgery should be reserved for patients with poor response, tumour progression or local relapse after radio-chemotherapy, or in cases of persistent vaginal fistula or total anal incontinence after the cessation of radio-chemotherapy. In the case of metastatic tumours, current therapeutic recommendations are based on less robust evidence; with chemotherapy playing a major role. CONCLUSION: These recommendations are permanently being reviewed, and each individual case must be discussed inside a multidisciplinary team.

18 Guideline Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stages I to IIIA Resectable Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update Summary. 2017

Kris, Mark G / Gaspar, Laurie E / Chaft, Jamie E / Kennedy, Erin B. ·University of Colorado School of Medicine, Anschutz, CO; Memorial Sloan Kettering Cancer Center, New York City, NY; and American Society of Clinical Oncology, Alexandria, VA. ·J Oncol Pract · Pubmed #28441082.

ABSTRACT: -- No abstract --

19 Guideline Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. 2017

Kris, Mark G / Gaspar, Laurie E / Chaft, Jamie E / Kennedy, Erin B / Azzoli, Christopher G / Ellis, Peter M / Lin, Steven H / Pass, Harvey I / Seth, Rahul / Shepherd, Frances A / Spigel, David R / Strawn, John R / Ung, Yee C / Weyant, Michael. ·Mark G. Kris and Jamie E. Chaft, Memorial Sloan Kettering Cancer Center · Harvey I. Pass, New York University Langone Medical Center, New York · Rahul Seth, Upstate Medical Center, Syracuse University, Syracuse, NY · Laurie E. Gaspar and Michael Weyant, University of Colorado School of Medicine, Aurora, CO · Erin B. Kennedy, American Society of Clinical Oncology, Alexandria, VA · Christopher G. Azzoli, Massachusetts General Hospital, Boston, MA · Steven H. Lin, MD Anderson Cancer Center · John R. Strawn, Patient Representative, Houston, TX · David R. Spigel, Sarah Cannon Cancer Center, Nashville, TN · Peter M. Ellis, Juravinski Cancer Center, Hamilton Health Sciences, Hamilton · Frances A. Shepherd, Princess Margaret Cancer Centre, University Health Network · and Yee C. Ung, Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada. ·J Clin Oncol · Pubmed #28437162.

ABSTRACT: Purpose The panel updated the American Society of Clinical Oncology (ASCO) adjuvant therapy guideline for resected non-small-cell lung cancers. Methods ASCO convened an update panel and conducted a systematic review of the literature, investigating adjuvant therapy in resected non-small-cell lung cancers. Results The updated evidence base covered questions related to adjuvant systemic therapy and included a systematic review conducted by Cancer Care Ontario current to January 2016. A recent American Society for Radiation Oncology guideline and systematic review, previously endorsed by ASCO, was used as the basis for recommendations for adjuvant radiation therapy. An update of these systematic reviews and a search for studies related to radiation therapy found no additional randomized controlled trials. Recommendations Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with stage IIA, IIB, or IIIA disease who have undergone complete surgical resections. For individuals with stage IB, adjuvant cisplatin-based chemotherapy is not recommended for routine use. However, a postoperative multimodality evaluation, including a consultation with a medical oncologist, is recommended to assess benefits and risks of adjuvant chemotherapy for each patient. The guideline provides information on factors other than stage to consider when making a recommendation for adjuvant chemotherapy, including tumor size, histopathologic features, and genetic alterations. Adjuvant chemotherapy is not recommended for patients with stage IA disease. Adjuvant radiation therapy is not recommended for patients with resected stage I or II disease. In patients with stage IIIA N2 disease, adjuvant radiation therapy is not recommended for routine use. However, a postoperative multimodality evaluation, including a consultation with a radiation oncologist, is recommended to assess benefits and risks of adjuvant radiation therapy for each patient with N2 disease. Additional information is available at www.asco.org/lung-cancer-guidelines and www.asco.org/guidelineswiki .

20 Guideline Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. 2017

Ettinger, David S / Wood, Douglas E / Aisner, Dara L / Akerley, Wallace / Bauman, Jessica / Chirieac, Lucian R / D'Amico, Thomas A / DeCamp, Malcolm M / Dilling, Thomas J / Dobelbower, Michael / Doebele, Robert C / Govindan, Ramaswamy / Gubens, Matthew A / Hennon, Mark / Horn, Leora / Komaki, Ritsuko / Lackner, Rudy P / Lanuti, Michael / Leal, Ticiana A / Leisch, Leah J / Lilenbaum, Rogerio / Lin, Jules / Loo, Billy W / Martins, Renato / Otterson, Gregory A / Reckamp, Karen / Riely, Gregory J / Schild, Steven E / Shapiro, Theresa A / Stevenson, James / Swanson, Scott J / Tauer, Kurt / Yang, Stephen C / Gregory, Kristina / Hughes, Miranda. · ·J Natl Compr Canc Netw · Pubmed #28404761.

ABSTRACT: This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.

21 Guideline Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. 2017

Finelli, Antonio / Ismaila, Nofisat / Bro, Bill / Durack, Jeremy / Eggener, Scott / Evans, Andrew / Gill, Inderbir / Graham, David / Huang, William / Jewett, Michael A S / Latcha, Sheron / Lowrance, William / Rosner, Mitchell / Shayegan, Bobby / Thompson, R Houston / Uzzo, Robert / Russo, Paul. ·Antonio Finelli and Michael A.S. Jewett, Princess Margaret Cancer Center · Andrew Evans, University Health Network, Toronto · Bobby Shayegan, St Joseph Hospital, Hamilton, Ontario, Canada · Nofisat Ismaila, American Society of Clinical Oncology, Alexandria · Mitchell Rosner, University of Virginia School of Medicine, Charlottesville, VA · Bill Bro, Kidney Cancer Association · Scott Eggener, University of Chicago, Chicago, IL · Jeremy Durack, Sheron Latcha, and Paul Russo, Memorial Sloan Kettering Cancer Center · William Huang, New York University Langone Medical Center, New York, NY · Inderbir Gill, University of Southern California, Los Angeles, CA · David Graham, Levine Cancer Institute, Charlotte, NC · William Lowrance, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT · R. Houston Thompson, Mayo Clinic, Rochester, MN · and Robert Uzzo, Fox Chase Cancer Center, Philadelphia, PA. ·J Clin Oncol · Pubmed #28095147.

ABSTRACT: Purpose To provide recommendations for the management options for patients with small renal masses (SRMs). Methods By using a literature search and prospectively defined study selection, we sought systematic reviews, meta-analyses, randomized clinical trials, prospective comparative observational studies, and retrospective studies published from 2000 through 2015. Outcomes included recurrence-free survival, disease-specific survival, and overall survival. Results Eighty-three studies, including 20 systematic reviews and 63 primary studies, met the eligibility criteria and form the evidentiary basis for the guideline recommendations. Recommendations On the basis of tumor-specific findings and competing risks of mortality, all patients with an SRM should be considered for a biopsy when the results may alter management. Active surveillance should be an initial management option for patients who have significant comorbidities and limited life expectancy. Partial nephrectomy (PN) for SRMs is the standard treatment that should be offered to all patients for whom an intervention is indicated and who possess a tumor that is amenable to this approach. Percutaneous thermal ablation should be considered an option if complete ablation can reliably be achieved. Radical nephrectomy for SRMs should only be reserved for patients who possess a tumor of significant complexity that is not amenable to PN or for whom PN may result in unacceptable morbidity even when performed at centers with expertise. Referral to a nephrologist should be considered if chronic kidney disease (estimated glomerular filtration rate < 45 mL/min/1.73 m

22 Guideline CIRSE Guidelines on Percutaneous Ablation of Small Renal Cell Carcinoma. 2017

Krokidis, Miltiadis E / Orsi, Franco / Katsanos, Konstantinos / Helmberger, Thomas / Adam, Andy. ·Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. mkrokidis@hotmail.com. · Unit of Interventional Radiology, European Institute of Oncology, Milan, Italy. · Department of Radiology, Guy's and St Thomas' NHS Foundation Trust, London, UK. · Department of Diagnostic and Interventional Radiology, Neuroradiology and Nuclear Medicine, Klinikum Munich, Bogenhausen, Munich, Germany. ·Cardiovasc Intervent Radiol · Pubmed #27987000.

ABSTRACT: -- No abstract --

23 Guideline Recommendations of the Spanish Society of Pneumology and Thoracic Surgery on the diagnosis and treatment of non-small-cell lung cancer. 2016

Álvarez, Felipe Villar / Trueba, Ignacio Muguruza / Sanchis, José Belda / López-Rodó, Laureano Molins / Rodríguez Suárez, Pedro Miguel / de Cos Escuín, Julio Sánchez / Barreiro, Esther / Henar Borrego Pintado, M / Vicente, Carlos Disdier / Aldeyturriaga, Javier Flandes / Gámez García, Pablo / Garrido López, Pilar / León Atance, Pablo / Izquierdo Elena, José Miguel / Novoa Valentín, Nuria M / Rivas de Andrés, Juan José / Crespo, Íñigo Royo / Velázquez, Ángel Salvatierra / Seijo Maceiras, Luis M / Reina, Segismundo Solano / Bujanda, David Aguiar / Ávila Martínez, Régulo J / de Granda Orive, José Ignacio / Martínez, Eva de Higes / Gude, Vicente Díaz-Hellín / Flor, Raúl Embún / Freixinet Gilart, Jorge L / García Jiménez, María Dolores / Alarza, Fátima Hermoso / Sarmiento, Samuel Hernández / Honguero Martínez, Antonio Francisco / Jiménez Ruiz, Carlos A / Sanz, Iker López / Mariscal de Alba, Andrea / Martínez Vallina, Primitivo / Menal Muñoz, Patricia / Pérez, Laura Mezquita / Olmedo García, María Eugenia / Rombolá, Carlos A / Arregui, Íñigo San Miguel / Somiedo Gutiérrez, María Del Valle / Triviño Ramírez, Ana Isabel / Trujillo Reyes, Joan Carles / Vallejo, Carmen / Lozano, Paz Vaquero / Simó, Gonzalo Varela / Zulueta, Javier J. ·Servicio de Neumología, IIS Fundación Jiménez Díaz, UAM, CIBERES, Madrid, España. Electronic address: fvillarleon@yahoo.es. · Departamento de Cirugía Torácica, Hospitales Idcsalud, Madrid, España. · Servicio de Cirugía Torácica, Hospital Universitari Mútua Terrassa, Terrassa, Barcelona, España. · Servicio de Cirugía Torácica, Instituto Clínic Respiratori, Hospital Clínic, Barcelona, España. · Servicio de Cirugía Torácica, Hospital Universitario de Gran Canaria «Dr. Negrín», Las Palmas de Gran Canaria, España. · Sección de Neumología, Hospital San Pedro de Alcántara, Cáceres, España. · Grupo de Investigación en Desgaste Muscular y Caquexia en Enfermedades Crónicas Respiratorias y Cáncer de Pulmón, Instituto de Investigación del Hospital del Mar (IMIM)-Hospital del Mar, Departamento de Ciencias Experimentales y de la Salud (CEXS), Universidad Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona (PRBB), Barcelona y Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Barcelona, España. · Servicio de Anatomía Patológica, Hospital Clínico Universitario, Valladolid, España. · Servicio de Neumología, Hospital Clínico Universitario, Valladolid, España. · Unidad de Broncoscopias y Neumología Intervencionista, Servicio de Neumología, IIS Fundación Jiménez Díaz, UAM, CIBERES, Madrid, España. · Servicio de Cirugía Torácica, Hospital Universitario 12 de Octubre, Madrid, España. · Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid, España. · Servicio de Cirugía Torácica, Complejo Hospitalario Universitario de Albacete, Albacete, España. · Servicio de Cirugía Torácica, Hospital Universitario Donostia, San Sebastián, España. · Servicio de Cirugía Torácica, Complejo Asistencial Universitario de Salamanca, Salamanca, España. · Servicio de Cirugía Torácica, Hospital Universitario Miguel Servet, Hospital Clínico Universitario Lozano Blesa e IIS Aragón, Zaragoza, España. · Unidad de Cirugía Torácica y Trasplante Pulmonar, Hospital Universitario Reina Sofía, Córdoba, España. · Servicio de Neumología, IIS-Fundación Jiménez Díaz-CIBERES, Madrid, España. · Unidad de Tabaquismo, Servicio de Neumología, Hospital General Universitario Gregorio Marañón, Madrid, España. · Servicio de Oncología Médica, Hospital Universitario de Gran Canaria «Dr. Negrín», Las Palmas de Gran Canaria, España. · Servicio de Neumología, Hospital Universitario 12 de Octubre, Madrid, España. · Servicio de Neumología, Fundación Hospital Alcorcón, Alcorcón, Madrid, España. · Unidad Especializada de Tabaquismo, Comunidad Autónoma de Madrid, España. · Servicio de Radiología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España. · Servicio de Oncología Radioterápica, Hospital Universitario de Gran Canaria «Dr. Negrín», Las Palmas de Gran Canaria, España. · Servicio de Oncología Radioterápica, Hospital Universitario Ramón y Cajal, Madrid, España. · Servicio de Neumología, Clínica Universidad de Navarra, Pamplona, España. ·Arch Bronconeumol · Pubmed #27389767.

ABSTRACT: -- No abstract --

24 Guideline Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer. 2016

Villar Álvarez, Felipe / Muguruza Trueba, Ignacio / Belda Sanchis, José / Molins López-Rodó, Laureano / Rodríguez Suárez, Pedro Miguel / Sánchez de Cos Escuín, Julio / Barreiro, Esther / Borrego Pintado, M Henar / Disdier Vicente, Carlos / Flandes Aldeyturriaga, Javier / Gámez García, Pablo / Garrido López, Pilar / León Atance, Pablo / Izquierdo Elena, José Miguel / Novoa Valentín, Nuria M / Rivas de Andrés, Juan José / Royo Crespo, Íñigo / Salvatierra Velázquez, Ángel / Seijo Maceiras, Luís M / Solano Reina, Segismundo / Aguiar Bujanda, David / Avila Martínez, Régulo J / de Granda Orive, Jose Ignacio / de Higes Martinez, Eva / Diaz-Hellín Gude, Vicente / Embún Flor, Raúl / Freixinet Gilart, Jorge L / García Jiménez, María Dolores / Hermoso Alarza, Fátima / Hernández Sarmiento, Samuel / Honguero Martínez, Antonio Francisco / Jimenez Ruiz, Carlos A / López Sanz, Iker / Mariscal de Alba, Andrea / Martínez Vallina, Primitivo / Menal Muñoz, Patricia / Mezquita Pérez, Laura / Olmedo García, María Eugenia / Rombolá, Carlos A / San Miguel Arregui, Iñigo / de Valle Somiedo Gutiérrez, María / Triviño Ramírez, Ana Isabel / Trujillo Reyes, Joan Carles / Vallejo, Carmen / Vaquero Lozano, Paz / Varela Simó, Gonzalo / Zulueta, Javier J. ·Servicio de Neumología, IIS Fundación Jiménez Díaz, UAM, CIBERES, Madrid, España. Electronic address: fvillarleon@yahoo.es. · Departamento de Cirugía Torácica, Hospitales Idcsalud, Madrid, España. · Servicio de Cirugía Torácica, Hospital Universitari Mútua Terrassa, España. · Servicio de Cirugía Torácica, Instituto Clínic Respiratori, Hospital Clínic, Barcelona, España. · Servicio de Cirugía Torácica, Hospital Universitario de Gran Canaria «Dr. Negrín», España. · Sección de Neumología, Hospital San Pedro de Alcántara, Cáceres, España. · Grupo de Investigación en Desgaste Muscular y Caquexia en Enfermedades Crónicas Respiratorias y Cáncer de Pulmón, Instituto de Investigación del Hospital del Mar (IMIM)-Hospital del Mar, Departamento de Ciencias Experimentales y de la Salud (CEXS), Universidad Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona (PRBB); Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Barcelona. España. · Servicio de Anatomía Patológica, Hospital Clínico Universitario, Valladolid, España. · Servicio de Neumología, Hospital Clínico Universitario, Valladolid, España. · Unidad de Broncoscopias y Neumología Intervencionista, Servicio de Neumología, ISS Fundación Jiménez Díaz, UAM, CIBERES, Madrid, España. · Servicio de Cirugía Torácica, Hospital Universitario 12 de Octubre, Madrid, España. · Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid, España. · Servicio de Cirugía Torácica, Complejo Hospitalario Universitario de Albacete, España. · Servicio de Cirugía Torácica, Hospital Universitario Donostia, España. · Servicio de Cirugía Torácica, Complejo Asistencial Universitario de Salamanca, España. · Hospital Universitario Miguel Servet, Hospital Clínico Universitario Lozano Blesa e IIS Aragón, Zaragoza, España. · Unidad de Cirugía Torácica y Trasplante Pulmonar, Hospital Universitario Reina Sofía, Córdoba, España. · Servicio de Neumología, IIS-Fundación Jiménez Díaz-CIBERES, Madrid, España. · Unidad de Tabaquismo, Servicio de Neumología H.G.U. Gregorio Marañón, Madrid, España. · Servicio de Oncología Médica, Hospital Universitario de Gran Canaria «Dr. Negrín», España. · Servicio de Neumología, Hospital 12 de Octubre, Madrid, España. · Servicio de Neumología, Fundación Hospital Alcorcón, Alcorcón, Madrid, España. · Unidad Especializada de Tabaquismo, Comunidad Autónoma de Madrid, España. · Servicio de Radiología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España. · Servicio de Oncología Radioterápica, Hospital Universitario de Gran Canaria «Dr. Negrín», España. · Servicio de Oncología Radioterápica, Hospital Universitario Ramón y Cajal, Madrid, España. · Servicio de Neumología, Clínica Universidad de Navarra, España. ·Arch Bronconeumol · Pubmed #27237592.

ABSTRACT: The Thoracic Surgery and Thoracic Oncology groups of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) have backed the publication of a handbook on recommendations for the diagnosis and treatment of non-small cell lung cancer. Due to the high incidence and mortality of this disease, the best scientific evidence must be constantly updated and made available for consultation by healthcare professionals. To draw up these recommendations, we called on a wide-ranging group of experts from the different specialties, who have prepared a comprehensive review, divided into 4 main sections. The first addresses disease prevention and screening, including risk factors, the role of smoking cessation, and screening programs for early diagnosis. The second section analyzes clinical presentation, imaging studies, and surgical risk, including cardiological risk and the evaluation of respiratory function. The third section addresses cytohistological confirmation and staging studies, and scrutinizes the TNM and histological classifications, non-invasive and minimally invasive sampling methods, and surgical techniques for diagnosis and staging. The fourth and final section looks at different therapeutic aspects, such as the role of surgery, chemotherapy, radiation therapy, a multidisciplinary approach according to disease stage, and other specifically targeted treatments, concluding with recommendations on the follow-up of lung cancer patients and surgical and endoscopic palliative interventions in advanced stages.

25 Guideline Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: CHEST Guideline and Expert Panel Report. 2016

Wahidi, Momen M / Herth, Felix / Yasufuku, Kazuhiro / Shepherd, Ray Wesley / Yarmus, Lonny / Chawla, Mohit / Lamb, Carla / Casey, Kenneth R / Patel, Sheena / Silvestri, Gerard A / Feller-Kopman, David J. ·Duke University Medical Center, Division of Pulmonary and Critical Care Medicine, Durham, NC. Electronic address: momen.wahidi@duke.edu. · Division of Pulmonary and Critical Care Medicine, University of Heidelberg, Heidelberg, Germany. · Division of Thoracic Surgery, Toronto General Hospital, University of Toronto, Toronto, ON, Canada. · Virginia Commonwealth University Medical Center, Richmond, VA. · Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD. · Division of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. · Division of Pulmonary and Critical Care Medicine, Lahey Clinic Hospital, Burlington, MA. · Division of Pulmonary and Critical Care, University of Wisconsin School of Medicine and Public Health, Madison, WI. · CHEST, Glenview, IL. · Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC. ·Chest · Pubmed #26402427.

ABSTRACT: BACKGROUND: Endobronchial ultrasound (EBUS) was introduced in the last decade, enabling real-time guidance of transbronchial needle aspiration (TBNA) of mediastinal and hilar structures and parabronchial lung masses. The many publications produced about EBUS-TBNA have led to a better understanding of the performance characteristics of this procedure. The goal of this document was to examine the current literature on the technical aspects of EBUS-TBNA as they relate to patient, technology, and proceduralist factors to provide evidence-based and expert guidance to clinicians. METHODS: Rigorous methodology has been applied to provide a trustworthy evidence-based guideline and expert panel report. A group of approved panelists developed key clinical questions by using the PICO (population, intervention, comparator, and outcome) format that addressed specific topics on the technical aspects of EBUS-TBNA. MEDLINE (via PubMed) and the Cochrane Library were systematically searched for relevant literature, which was supplemented by manual searches. References were screened for inclusion, and well-recognized document evaluation tools were used to assess the quality of included studies, to extract meaningful data, and to grade the level of evidence to support each recommendation or suggestion. RESULTS: Our systematic review and critical analysis of the literature on 15 PICO questions related to the technical aspects of EBUS-TBNA resulted in 12 statements: 7 evidence-based graded recommendations and 5 ungraded consensus-based statements. Three questions did not have sufficient evidence to generate a statement. CONCLUSIONS: Evidence on the technical aspects of EBUS-TBNA varies in strength but is satisfactory in certain areas to guide clinicians on the best conditions to perform EBUS-guided tissue sampling. Additional research is needed to enhance our knowledge regarding the optimal performance of this effective procedure.

Next